Cappuccio JM, Mehta N, Pellish R. Inpatient Infliximab Biosimilar Cost-Savings - Cost analysis of inpatient treatment with originator Infliximab (Remicade) vs biosimilar Infliximab (Renflexis) for acute severe ulcerative colitis.?. Dig Dis 2024 May 24. doi: 10.1159/000536303.
PMID: 38797170